Form 4: Beta Bionics Chief Medical Officer Acquires Stock Options

Steven Jon Russell, Chief Medical Officer of Beta Bionics, Inc., reports the acquisition of stock options.

Summary

• Steven Jon Russell, the Chief Medical Officer of Beta Bionics, Inc. (BBNX), filed a Form 4 with the SEC.
• The filing reports the acquisition of 90,637 employee stock options on January 29, 2025, with an exercise price of $17.
• The options vest monthly over a 48-month period starting January 29, 2025, and expire on January 28, 2035.
• Each share of Class B Common Stock subject to this option was converted into an equal number of shares of Common Stock immediately prior to the closing of the initial public offering.
• Following the transaction, Russell directly owns 90,637 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to stock options granted to a key executive. While the executive's confidence is a slight positive, the filing itself is standard.

Positives

• The acquisition of stock options by a key executive can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates confidence from a key executive.

Key Dates